Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with low-dose cytarabine (LDAC) in dose-escalation phase of trial
PR Newswire
SAN DIEGO, May 17, 2018
PR Newswire
SAN DIEGO, May 17, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey